
Amgen Inc.

AMGN (Amgen Inc.) trades at 6.2x EV/Revenue — reasonably priced for a biotech & healthcare company with best-in-class gross margins (71%) and mature growth profile. The business is highly profitable at 43% EBIT margins. Forward PE of 16x.
Companies that beat on both revenue AND EPS see an average 3.5% pop. Those that miss both drop 5.7% on average.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
Amgen is one of the world's largest independent biotechnology companies, developing and manufacturing innovative medicines for serious illnesses including cancer, kidney disease, rheumatoid arthritis, and cardiovascular conditions. They generate revenue by selling prescription drugs directly to healthcare providers and through partnerships with other pharmaceutical companies. Their business model relies on discovering breakthrough therapies, getting FDA approval, and then commercializing these treatments globally.
After several years of declining revenue due to biosimilar competition, Amgen is positioned for a return to growth driven by newer launches like Lumakras (cancer) and Tezspire (asthma). The company targets mid-single-digit revenue growth through 2030, supported by a robust pipeline addressing large market opportunities in oncology, inflammation, and metabolic diseases. Key growth catalysts include expanding into obesity treatments and next-generation cancer therapies.
Amgen maintains industry-leading profitability with gross margins consistently above 75% and operating margins in the mid-30s range. The company has demonstrated disciplined cost management while investing heavily in R&D, with free cash flow margins typically running 25-30% of revenue. Their established manufacturing capabilities and economies of scale provide sustainable competitive advantages in margin generation.
As a pioneer in biotechnology, Amgen competes with both large pharma companies (Roche, J&J, Pfizer) and biotech specialists across various therapeutic areas. Their key competitive advantages include deep expertise in protein engineering, world-class manufacturing capabilities, and strong relationships with oncology and nephrology specialists. However, they face increasing competition from nimble biotech companies and well-funded big pharma R&D programs.
Without access to recent earnings data, Amgen's recent performance likely reflects the ongoing transition from legacy blockbusters to newer growth drivers. The company has been actively advancing its pipeline through clinical trials and regulatory submissions while managing the headwinds from biosimilar competition. Investor focus remains on pipeline readouts and the company's ability to return to sustainable growth.
Analysts typically view Amgen as a defensive biotech play with steady cash flows but limited near-term growth catalysts. The consensus generally reflects cautious optimism about the pipeline potential balanced against concerns about the patent cliff timeline. Key debates likely center on the probability of success for late-stage pipeline assets and the company's ability to offset biosimilar headwinds.
Amgen is a mature biotech giant in transition, offering investors steady cash flows and dividend income while betting on pipeline innovation to reignite growth in the next 3-5 years.
Pre-generated investor questions answered by Claude Opus. Available in the Atlas AI tab.








| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | — | $37.8B | $38.9B | $39.8B |
| Growth | — | +3% | +2% | |
| EBITDA | — | $17.0B | $17.5B | $17.9B |
| Growth | — | +3% | +2% | |
| EPS (PF) | — | $22.41 | $23.35 | $24.22 |
| Growth | — |
TrumpRx lists many medicines at prices higher than paid in UK
GSK and Amgen to add medicines to TrumpRx, Fox Business reports
Amgen: MariTide And Osteoporosis Sales Fuel The Rally
Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
| +4% |
| +4% |